Skip to main content
. Author manuscript; available in PMC: 2021 Feb 22.
Published in final edited form as: Clin Gastroenterol Hepatol. 2020 Feb 13;18(13):2952–2961.e8. doi: 10.1016/j.cgh.2020.02.010

Table 2.

Final Multivariable Model for Corticosteroid-Free Remission With VDZ After 52 Weeks of Therapy

Variable Odds ratio 95% Cl
Previous TNF antagonist exposure (no vs yes) 1.758 1.194–2.587
Disease duration (≥2 y vs <2 y) 1.689 1.018–2.803
Baseline endoscopy (moderate vs severe) 1.447 0.991–2.114
Baseline albumin 1.067 1.024–1.112

CI, confidence interval; TNF, tumor necrosis factor; VDZ, vedolizumab.